Skip to main content
. 2022 Apr 22;47(7):1315–1330. doi: 10.1038/s41386-022-01322-4

Fig. 2. Opioid-sparing outcomes from clinical trials in people with cancer pain.

Fig. 2

Meta-analysis comparing cannabinoids with placebo on outcomes of a percent improvement in pain score, b change in mean total Oral Morphine Equivalent Daily Dose (OMEDD), c serious adverse events from baseline, and d adverse events excluding serious adverse events, in clinical trials of people with cancer pain.